Skip to main content

Quanterix Corp

For the period ended Sep 30, 2026. Filed Nov 9, 2026.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2026 · Filed Nov 9, 2026

QTRX$3.38+16.8%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Consolidated Statements of Operations

(in thousands, except per share data, unaudited)

Three Months Ended September 30,Nine Months Ended September 30,
2026202520262025
Revenues:
Product revenue$25,193$26,151$74,149$63,723
Service and other revenue9,35914,03628,75229,971
Collaboration and license revenue422461,3941,348
Total revenues34,97440,233104,29595,042
Costs of goods sold and services:
Cost of product revenue15,44716,68445,20838,619
Cost of service and other revenue6,0277,64817,34715,683
Total costs of goods sold and services21,47424,33262,55554,302
Gross profit13,50015,90141,74040,740
Operating expenses:
Research and development7,3728,00922,51627,126
Selling, general and administrative28,45338,04385,57599,561
Impairment and restructuring costs1717,17446,94014,844
Total operating expenses35,99653,226155,031141,531
Loss from operations(22,496)(37,325)(113,291)(100,791)
Other income (expense), net:
Interest income6631,4482,3167,408
Change in fair value of contingent liabilities595582,0173,952
Other income (expense), net(65)(178)21,117(68)
Loss before income taxes(21,303)(35,997)(87,841)(89,499)
Income tax benefit (expense)(288)2,480(227)5,466
Net loss$(21,591)$(33,517)$(88,068)$(84,033)
Net loss per common share, basic and diluted$(0.46)$(0.73)$(1.87)$(2.04)
Weighted-average common shares outstanding, basic and diluted47,38846,06047,17341,243
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.